On this page

Guidance on trigeminal neuralgia rests on a classification of the pain, two main clinical guidelines, and surgical and observational studies. There are few randomized trials, and most comparisons between procedures come from observational studies.

QuestionMain sources
What counts as TN, and what types are there?ICHD-3 classification
How is it diagnosed and treated?European Academy of Neurology guideline (2019); UK guideline (2021)
How well does microvascular decompression work?Holste review (2020); Danish five-year cohort (2025)
How do the procedures compare?Network meta-analysis (2026)

Classification and guidelines

The International Classification of Headache Disorders (ICHD-3) defines TN and its classical, secondary and idiopathic types, and separates purely paroxysmal pain from pain with a continuous component1. The European Academy of Neurology guideline covers imaging, the place of carbamazepine and oxcarbazepine, and when to consider surgery2. The UK guideline from the Royal College of Surgeons' Faculty of Dental Surgery describes assessment, including dental assessment, specialist follow-up of medicines, procedures and supportive care3.

Microvascular decompression

A 2020 review of 46 studies and 3,897 adults found that about 76% were free of pain without medication at an average follow-up of 1.7 years. Most studies were retrospective, and patients' TN types and previous surgery varied4. A prospective Danish study followed people with classical or idiopathic TN treated with MVD or medicines for five years, with treatment chosen clinically rather than at random5.

Comparing procedures

A 2026 network meta-analysis compared MVD, percutaneous procedures and radiosurgery for pain relief, recurrence, facial numbness and complications. It rated the certainty of the evidence as low to very low, mainly because the studies were observational6. A 2025 Chinese expert consensus covers classification, diagnosis, imaging and treatment of idiopathic and secondary TN7.

Patient information

Johns Hopkins Medicine8 and the NHS9 describe symptoms and assessment. Mayfield Brain & Spine explains MVD and what to watch for afterward10. The NHS describes the treatment options11 and the safety warnings for carbamazepine12.

References

  1. International Headache Society. ICHD-3, sections 13.1.1–13.1.2 (2018). Source ↩
  2. Bendtsen L et al. European Academy of Neurology guideline. Eur J Neurol. 2019;26:831–849. Source ↩
  3. McMillan R et al. Guidelines for the management of trigeminal neuralgia. RCS England Faculty of Dental Surgery, 2021. Source ↩
  4. Holste K, Chan AY, Rolston JD, Englot DJ. Pain outcomes following MVD for drug-resistant TN: systematic review and meta-analysis. Neurosurgery. 2020;86:182–190. Source ↩
  5. Worm J et al. Five-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia. J Neurol. 2025. Source ↩
  6. Fonseca PEO et al. From MVD to radiosurgery: network meta-analysis. Neurosurg Rev. 2026;49:261. PMID 41793527. PubMed ↩
  7. Chinese Medical Doctor Association committees and International Association of Neurorestoratology. Expert consensus (2025 edition). Zhonghua Yi Xue Za Zhi. 2025;105:2058–2071. PMID 40619965. PubMed ↩
  8. Johns Hopkins Medicine. Trigeminal Neuralgia (patient information). Source ↩
  9. NHS. Trigeminal neuralgia: diagnosis. Source ↩
  10. Mayfield Brain & Spine. Microvascular decompression (patient information). Source ↩
  11. NHS. Trigeminal neuralgia: treatment. Source ↩
  12. NHS. Carbamazepine (Tegretol). Source ↩